Quest plans to refine, develop and validate the technology and is aiming to launch the test in North America next year.

Quest Diagnostics Incorporated (NYSE:DGX), a prominent provider of diagnostic testing and information services, has hit a record-breaking share price of $180.11, pushing the company’s market ...

Robert W. Baird analyst Eric Coldwell maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $797.00. The company’s shares opened today at ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quest Diagnostics with a $188.83 average price target. Based on Quest Diagnostics’ latest earnings release ...

34 analyst firms have reported ratings in the last year. The last upgrade for Quest Diagnostics Inc happened on January 6, 2025 when Leerink Partners raised their price target to $174. Leerink ...

Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting ...

Bank of America upped their price target on shares of Quest Diagnostics from $179.00 to $182.00 and gave the company a “buy” rating in a research note on Friday, December 13th. UBS Group ...

Redburn-Atlantic sets Quest stock Buy rating, $195 target Open in App Get 45% Off Sign In Free Sign Up ...